Quinones et al v. Frequency Therapeutics, Inc. et al

Track this case

Case Number:

1:21-cv-10933

Court:

Massachusetts

Nature of Suit:

Securities/Commodities

Multi Party Litigation:

Class Action

Judge:

William G. Young

Firms

Companies

Sectors & Industries:

  1. November 04, 2024

    Late New Evidence Can't Revive Investor Suit, Judge Says

    A Massachusetts federal judge has declined to vacate the dismissal of an investor class action alleging that a hearing loss treatment company and some of its executives concealed disappointing clinical trial results, saying the plaintiff "is playing fast and loose with the Rules of Civil Procedure," and trying to blame the court and the clerk for his own procedural missteps.

  2. July 03, 2024

    1st Circ. Hands Hearing Loss Biotech Win In Stock-Drop Suit

    A panel of the First Circuit declined to revive an investor class action alleging that a hearing loss treatment company and some of its executives concealed disappointing clinical trial results, saying there was no evidence the company had knowingly made false statements about the trial.

  3. March 30, 2023

    Hearing Loss Biotech Escapes Investors' Stock Suit

    Massachusetts hearing loss treatment company Frequency Therapeutics escaped a class action alleging it lied to investors when it said a clinical trial was going according to plan.

  4. August 03, 2021

    3 Firms Vie To Lead Investor Suit Against Mass. Biotech Co.

    Glancy Prongay & Murray LLP, Levi & Korinsky LLP and Scott+Scott Attorneys at Law LLPĀ filed competing bids in Massachusetts federal court Monday to represent investors in a class action against Frequency Therapeutics Inc. for allegedly hiding bad clinical trial results while executives dumped their stakes in the Massachusetts biotech company.

  5. June 04, 2021

    Hearing Loss Biotech Sued By Investor Over 78% Stock Drop

    Frequency Therapeutics Inc. and its chief executive hid disastrous clinical trial results that undermined the prospects of its lead hearing loss treatment while dumping shares before the findings became public, an investor in the Massachusetts company said in a putative class action filed Thursday.